{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:32:53Z","timestamp":1786116773339,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Princess Nourah bint Abdulrahman University, Researchers Supporting Project","award":["PNURSP2026R386"],"award-info":[{"award-number":["PNURSP2026R386"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"DOI":"10.1186\/s13643-026-03215-9","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:54:58Z","timestamp":1780451698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Benralizumab in severe eosinophilic asthma: a comprehensive systematic review and meta-analysis of randomized controlled trials evaluating lung function, asthma control, and safety outcomes"],"prefix":"10.1186","volume":"15","author":[{"given":"Abbas","family":"Al Mutair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Alabbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan F.","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Alyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa Mohmmed","family":"Al-Shammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Awad","family":"Al-Omari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman A.","family":"Bomozah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Aljarameez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1415-4970","authenticated-orcid":false,"given":"Muhammad","family":"Daniyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"3215_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-204","volume":"12","author":"T To","year":"2012","unstructured":"To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional World Health Survey. BMC Public Health. 2012;12:204.","journal-title":"BMC Public Health"},{"issue":"2","key":"3215_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation, and treatment of severe asthma. Eur Respir J. 2014;43(2):343\u201373.","journal-title":"Eur Respir J"},{"key":"3215_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2147\/JAA.S211246","volume":"12","author":"G Tomisa","year":"2019","unstructured":"Tomisa G, Horv\u00e1th A, Szalai Z, M\u00fcller V, Tam\u00e1si L. Prevalence and impact of risk factors for poor asthma outcomes in a large, specialist-managed patient cohort: a real-life study. J Asthma Allergy. 2019;12:297\u2013307.","journal-title":"J Asthma Allergy"},{"issue":"2","key":"3215_CR4","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1378\/chest.12-0412","volume":"143","author":"PM O'Byrne","year":"2013","unstructured":"O\u2019Byrne PM, Pedersen S, Schatz M, Thoren A, Ekholm E, Carlsson LG, et al. The poorly explored impact of uncontrolled asthma. Chest. 2013;143(2):511\u201323.","journal-title":"Chest"},{"issue":"4","key":"3215_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.iac.2007.09.003","volume":"27","author":"JY Zhang","year":"2007","unstructured":"Zhang JY, Wenzel SE. Tissue and BAL-based biomarkers in asthma. Immunol Allergy Clin North Am. 2007;27(4):623\u201332.","journal-title":"Immunol Allergy Clin North Am"},{"key":"3215_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JAA.S111170","volume":"9","author":"D Price","year":"2016","unstructured":"Price D, Wilson AM, Chisholm A, Rigazio A, Burden A, Thomas M, et al. Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice. J Asthma Allergy. 2016;9:1\u201312.","journal-title":"J Asthma Allergy"},{"issue":"1","key":"3215_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005748","volume":"5","author":"D Talini","year":"2015","unstructured":"Talini D, Novelli F, Bacci E, Bartoli M, Cianchetti S, Costa F, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5(1):e005748.","journal-title":"BMJ Open"},{"issue":"2","key":"3215_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/resp.13730","volume":"25","author":"LP Chung","year":"2020","unstructured":"Chung LP, Upham JW, Bardin PG, Hew M. Rational oral corticosteroid use in adult severe asthma: a narrative review. Respirology. 2020;25(2):161\u201372.","journal-title":"Respirology"},{"issue":"5","key":"3215_CR9","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01486-2017","volume":"50","author":"A Bourdin","year":"2017","unstructured":"Bourdin A, Molinari N, Vachier I, Pahus L, Suehs C, Chanez P. Mortality: a neglected outcome in OCS-treated severe asthma. Eur Respir J. 2017;50(5):1701486.","journal-title":"Eur Respir J"},{"issue":"6","key":"3215_CR10","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1210\/jc.2015-1218","volume":"100","author":"LH Broersen","year":"2015","unstructured":"Broersen LH, Pereira AM, J\u00f8rgensen JO, Dekkers OM. Adrenal insufficiency in corticosteroid use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(6):2171\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3215_CR11","doi-asserted-by":"publisher","first-page":"1902290","DOI":"10.1183\/13993003.02273-2019","volume":"56","author":"AM Nanzer","year":"2020","unstructured":"Nanzer AM, Chowdhury A, Raheem A, Roxas C, Fernandes M, Thomson L, et al. Prevalence and recovery of adrenal insufficiency in steroid-dependent asthma patients receiving biologic therapy. Eur Respir J. 2020;56(1):1902290.","journal-title":"Eur Respir J"},{"issue":"4","key":"3215_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.31887\/DCNS.2006.8.4\/ssmith","volume":"8","author":"SM Smith","year":"2006","unstructured":"Smith SM, Vale WW. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci. 2006;8(4):383\u201395.","journal-title":"Dialogues Clin Neurosci"},{"issue":"10","key":"3215_CR13","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1016\/j.jaip.2020.06.055","volume":"8","author":"R Zeiger","year":"2020","unstructured":"Zeiger R, Sullivan P, Chung Y, Kreindler JL, Zimmerman NM, Tkacz J. Systemic corticosteroid-related complications and costs in adults with persistent asthma. J Allergy Clin Immunol Pract. 2020;8(10):3455-65.e13.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"3215_CR14","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","volume":"136","author":"P Lefebvre","year":"2015","unstructured":"Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. Journal of Allergy and Clinical Immunology. 2015;136(6):1488\u201395.","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"3215_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","volume":"11","author":"DB Price","year":"2018","unstructured":"Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193\u2013204.","journal-title":"J Asthma Allergy"},{"issue":"2","key":"3215_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/joim.13273","volume":"290","author":"M Gurnell","year":"2021","unstructured":"Gurnell M, Heaney LG, Price D, Menzies-Gow A. Long-term corticosteroid use, adrenal insufficiency and the need for steroid-sparing treatment in adult severe asthma. J Intern Med. 2021;290(2):240\u201356.","journal-title":"J Intern Med"},{"issue":"9","key":"3215_CR17","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/NEJMra1807486","volume":"381","author":"RL Rushworth","year":"2019","unstructured":"Rushworth RL, Torpy DJ, Falhammar H. Adrenal crisis. N Engl J Med. 2019;381(9):852\u201361.","journal-title":"N Engl J Med"},{"issue":"1","key":"3215_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","volume":"143","author":"W Busse","year":"2019","unstructured":"Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. Journal of Allergy and Clinical Immunology. 2019;143(1):190-200.e20.","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"3215_CR19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12931-019-1138-3","volume":"20","author":"A Edris","year":"2019","unstructured":"Edris A, De Feyter S, Maes T, Joos G, Lahousse L. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis. Respir Res. 2019;20(1):179.","journal-title":"Respir Res"},{"issue":"6","key":"3215_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","volume":"125","author":"R Kolbeck","year":"2010","unstructured":"Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344-53.e2.","journal-title":"J Allergy Clin Immunol"},{"key":"3215_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.rmed.2016.01.003","volume":"111","author":"TH Pham","year":"2016","unstructured":"Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21\u20139.","journal-title":"Respir Med"},{"issue":"10056","key":"3215_CR22","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","volume":"388","author":"ER Bleecker","year":"2016","unstructured":"Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. The Lancet. 2016;388(10056):2115\u201327.","journal-title":"The Lancet"},{"issue":"25","key":"3215_CR23","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","volume":"376","author":"P Nair","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of Benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448\u201358.","journal-title":"N Engl J Med"},{"issue":"1","key":"3215_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","volume":"6","author":"JM FitzGerald","year":"2018","unstructured":"FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, et al. Predictors of enhanced response with Benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51\u201364.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3215_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S2213-2600(17)30343-0","volume":"6","author":"M Humbert","year":"2018","unstructured":"Humbert M. Increasing confidence in the therapeutic relevance of eosinophils in severe asthma. Lancet Respir Med. 2018;6(1):7\u20138.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"3215_CR26","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00936-2018","volume":"52","author":"ER Bleecker","year":"2018","unstructured":"Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, et al. Baseline patient factors impact on the clinical efficacy of Benralizumab for severe asthma. Eur Respir J. 2018;52(4):1800936.","journal-title":"Eur Respir J"},{"issue":"1","key":"3215_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","volume":"7","author":"WW Busse","year":"2019","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-term safety and efficacy of Benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46\u201359.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"3215_CR28","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","volume":"150","author":"A Akenroye","year":"2022","unstructured":"Akenroye A, Lassiter G, Jackson JW, Keet C, Segal J, Alexander GC, et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis. J Allergy Clin Immunol. 2022;150(5):1097\u2013105.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"3215_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/biom15040544","volume":"15","author":"M Shiomi","year":"2025","unstructured":"Shiomi M, Watanabe R, Ishihara R, Tanaka S, Nakazawa T, Hashimoto M. Comparative insights on IL-5 targeting with mepolizumab and benralizumab: enhancing EGPA treatment strategies. Biomolecules. 2025;15(4):544.","journal-title":"Biomolecules"},{"key":"3215_CR30","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2019","unstructured":"Chandler J, Cumpston M, Li T, Page MJ, Welch VJ, editors. Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Chichester (UK): John Wiley & Sons; 2019.","edition":"2"},{"issue":"5","key":"3215_CR31","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341.","journal-title":"Int J Surg"},{"key":"3215_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3215_CR33","unstructured":"The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, 2014."},{"key":"3215_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/JAA.S240044","volume":"13","author":"RA Panettieri Jr","year":"2020","unstructured":"Panettieri RA Jr, Welte T, Shenoy KV, Korn S, Jandl M, Kerwin EM, et al. Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with Benralizumab for patients with severe eosinophilic asthma: Phase IIIb randomized, controlled trial (SOLANA). J Asthma Allergy. 2020;13:115\u201326.","journal-title":"J Asthma Allergy"},{"issue":"10056","key":"3215_CR35","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","volume":"388","author":"JM FitzGerald","year":"2016","unstructured":"FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128\u201341.","journal-title":"Lancet"},{"issue":"7","key":"3215_CR36","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S2213-2600(17)30190-X","volume":"5","author":"GT Ferguson","year":"2017","unstructured":"Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5(7):568\u201376.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"3215_CR37","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jaci.2013.05.020","volume":"132","author":"M Laviolette","year":"2013","unstructured":"Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086-96.e5.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3215_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000444799","volume":"169","author":"HS Park","year":"2016","unstructured":"Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016;169(3):135\u201345.","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"3215_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.alit.2017.10.004","volume":"67","author":"K Ohta","year":"2018","unstructured":"Ohta K, Adachi M, Tohda Y, Kamei T, Kato M, Fitzgerald JM, et al. Efficacy and safety of benralizumab in Japanese patients with severe, uncontrolled eosinophilic asthma. Allergol Int. 2018;67(2):266\u201372.","journal-title":"Allergol Int"},{"issue":"5","key":"3215_CR40","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.anai.2018.01.030","volume":"120","author":"BE Chipps","year":"2018","unstructured":"Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504-11.e4.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"3215_CR41","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","volume":"2","author":"M Castro","year":"2014","unstructured":"Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor \u03b1 monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879\u201390.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3215_CR42","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/all.14902","volume":"77","author":"GW Canonica","year":"2022","unstructured":"Canonica GW, Harrison TW, Chanez P, Menzella F, Louis R, Cosio BG, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2022;77(1):150\u201361.","journal-title":"Allergy"},{"issue":"3","key":"3215_CR43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","volume":"9","author":"TW Harrison","year":"2021","unstructured":"Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9(3):260\u201374.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"3215_CR44","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1016\/j.jaip.2021.07.058","volume":"9","author":"S Korn","year":"2021","unstructured":"Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, et al. Integrated safety and efficacy among patients receiving Benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021;9(12):4381-92.e4.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10423","key":"3215_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","volume":"403","author":"DJ Jackson","year":"2024","unstructured":"Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, et al. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. The Lancet. 2024;403(10423):271\u201381.","journal-title":"The Lancet"},{"issue":"1","key":"3215_CR46","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaci.2021.02.009","volume":"148","author":"WW Busse","year":"2021","unstructured":"Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Brooks L, et al. Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. J Allergy Clin Immunol. 2021;148(1):266-71.e2.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3215_CR47","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","volume":"185","author":"KW McGrath","year":"2012","unstructured":"McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012;185(6):612\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"3215_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-4-2","volume":"4","author":"J Joseph","year":"2004","unstructured":"Joseph J, Benedict S, Safa W, Joseph M. Serum interleukin-5 levels are elevated in mild and moderate persistent asthma irrespective of regular inhaled glucocorticoid therapy. BMC Pulm Med. 2004;4:2.","journal-title":"BMC Pulm Med"},{"key":"3215_CR49","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12931-015-0299-y","volume":"16","author":"PE Silkoff","year":"2015","unstructured":"Silkoff PE, Strambu I, Laviolette M, Singh D, FitzGerald JM, Lam S, et al. Asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) longitudinal profiling study. Respir Res. 2015;16:142.","journal-title":"Respir Res"},{"issue":"3","key":"3215_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/all.12816","volume":"71","author":"CD Rudulier","year":"2016","unstructured":"Rudulier CD, Larch\u00e9 M, Moldaver D. Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity. Allergy. 2016;71(3):283\u20135.","journal-title":"Allergy"},{"issue":"13","key":"3215_CR51","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198\u2013207.","journal-title":"N Engl J Med"},{"issue":"7","key":"3215_CR52","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549\u201356.","journal-title":"Lancet Respir Med"},{"issue":"9842","key":"3215_CR53","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651\u20139.","journal-title":"Lancet"},{"issue":"5","key":"3215_CR54","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","volume":"3","author":"M Castro","year":"2015","unstructured":"Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355\u201366.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"3215_CR55","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","volume":"119","author":"WC Moore","year":"2007","unstructured":"Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute\u2019s Severe Asthma Research Program. J Allergy Clin Immunol. 2007;119(2):405\u201313.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"3215_CR56","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.rmed.2014.04.014","volume":"108","author":"K Matsunaga","year":"2014","unstructured":"Matsunaga K, Ichikawa T, Oka A, Morishita Y, Kanai K, Hiramatsu M, et al. Changes in forced expiratory volume in 1 second over time in patients with controlled asthma at baseline. Respir Med. 2014;108(7):976\u201382.","journal-title":"Respir Med"},{"issue":"1","key":"3215_CR57","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jaci.2013.03.044","volume":"132","author":"AT Hastie","year":"2013","unstructured":"Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol. 2013;132(1):72\u201380.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3215_CR58","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jaci.2010.02.008","volume":"125","author":"AT Hastie","year":"2010","unstructured":"Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125(5):1028-36.e13.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13643-026-03215-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-026-03215-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:02:20Z","timestamp":1786017740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13643-026-03215-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3215"],"URL":"https:\/\/doi.org\/10.1186\/s13643-026-03215-9","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"212"}}